Uncommon Cents Investing LLC Buys 520 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Uncommon Cents Investing LLC boosted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,796 shares of the medical equipment provider’s stock after acquiring an additional 520 shares during the period. Uncommon Cents Investing LLC’s holdings in Zimmer Biomet were worth $2,653,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in ZBH. Fairfield Bush & CO. bought a new stake in Zimmer Biomet in the first quarter valued at approximately $111,000. United Bank boosted its holdings in shares of Zimmer Biomet by 4.1% during the 1st quarter. United Bank now owns 11,072 shares of the medical equipment provider’s stock worth $1,416,000 after buying an additional 437 shares in the last quarter. Panagora Asset Management Inc. boosted its holdings in shares of Zimmer Biomet by 153.9% during the 1st quarter. Panagora Asset Management Inc. now owns 9,803 shares of the medical equipment provider’s stock worth $1,254,000 after buying an additional 5,942 shares in the last quarter. Aviva PLC boosted its holdings in shares of Zimmer Biomet by 0.4% during the 1st quarter. Aviva PLC now owns 30,636 shares of the medical equipment provider’s stock worth $3,918,000 after buying an additional 137 shares in the last quarter. Finally, Allianz Asset Management GmbH boosted its holdings in shares of Zimmer Biomet by 11.2% during the 1st quarter. Allianz Asset Management GmbH now owns 41,816 shares of the medical equipment provider’s stock worth $5,348,000 after buying an additional 4,224 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ZBH. Canaccord Genuity Group reaffirmed a “hold” rating and set a $130.00 target price on shares of Zimmer Biomet in a research report on Friday, February 23rd. Raymond James upped their target price on Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Truist Financial upped their target price on Zimmer Biomet from $133.00 to $135.00 and gave the stock a “hold” rating in a research report on Friday, February 9th. JPMorgan Chase & Co. upped their target price on Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research report on Friday, February 9th. Finally, Morgan Stanley increased their price target on Zimmer Biomet from $120.00 to $125.00 and gave the company an “equal weight” rating in a research report on Monday, December 4th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $137.84.

Zimmer Biomet Stock Down 0.5 %

ZBH stock opened at $131.98 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61. The company has a market capitalization of $27.07 billion, a price-to-earnings ratio of 26.99, a PEG ratio of 2.44 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $102.00 and a fifty-two week high of $149.25. The stock has a fifty day moving average of $125.46 and a 200-day moving average of $118.13.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping the consensus estimate of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. During the same quarter in the prior year, the company earned $1.88 EPS. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. As a group, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 annualized dividend and a yield of 0.73%. Zimmer Biomet’s dividend payout ratio is currently 19.63%.

Insiders Place Their Bets

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the transaction, the vice president now owns 44,145 shares in the company, valued at approximately $5,677,929.90. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.95% of the stock is owned by corporate insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.